---
title: MDR and Brexit: Selling Medical Devices in the UK as an EU Startup
description: How Brexit changed medical device regulation for EU startups selling to the UK. UKCA marking, CE marking recognition, UK Approved Bodies, and practical market access strategies.
authors: Tibor Zechmeister, Felix Lenhard
category: MDR Fundamentals & Regulatory Strategy
primary_keyword: 
canonical_url: https://zechmeister-solutions.com/en/blog/mdr-and-brexit-selling-medical-devices-uk-eu-startup
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# MDR and Brexit: Selling Medical Devices in the UK as an EU Startup

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

Brexit created a regulatory fracture in one of the world's most integrated medical device markets. Before 31 January 2020, EU and UK medical device regulation was the same — one set of rules, one CE mark, one market of over 500 million people. After Brexit, the UK became a separate regulatory jurisdiction with its own rules, its own marking, and its own approval bodies.

For EU MedTech startups, the UK remains an attractive market — approximately 70 million people, a well-funded NHS, a strong private healthcare sector, and a culture of medical technology adoption. But accessing that market now requires navigating a distinct regulatory pathway.

This post maps the current UK regulatory landscape for medical devices and provides practical guidance for EU startups planning to sell across the Channel.

## The UK Regulatory Framework Post-Brexit

The UK's medical device regulatory framework is based on the **UK Medical Devices Regulations 2002 (as amended)**, which is derived from the old EU directives (MDD and AIMDD) rather than MDR. The Medicines and Healthcare products Regulatory Agency (MHRA) is the competent authority. 

### The Original Plan: UKCA Marking

The UK government originally planned to replace CE marking with UKCA (UK Conformity Assessed) marking for the UK market. Under this plan, all medical devices placed on the UK market would need to bear the UKCA mark, assessed by UK Approved Bodies.

### The Reality: Extended CE Mark Recognition

In practice, the UK has repeatedly extended the period during which CE-marked medical devices can be placed on the UK market without UKCA marking. The practical implementation of full UKCA-only requirements has been delayed multiple times. 

As of 2026, the situation is: 

This ongoing uncertainty has made planning difficult for EU startups. The regulatory goalposts have moved several times, and manufacturers have had to maintain flexibility in their market access strategies.

## Current Routes to the UK Market

### Route 1: CE Marking (While Still Accepted)

If the UK is still accepting CE-marked devices (check the current status above), this is the simplest route for an EU startup. Your MDR CE mark — or your MDD/AIMDD CE mark under the EU transition provisions — allows you to place your device on the UK market without additional UK-specific conformity assessment.

**Advantages:**
- No additional regulatory work beyond what you have done for the EU
- No UK Approved Body involvement needed
- Fastest route to the UK market

**Limitations:**
- Temporary — the acceptance of CE marking will end at some point
- You must still comply with UK-specific requirements (see below)

### Route 2: UKCA Marking

UKCA marking requires conformity assessment by a UK Approved Body — the UK equivalent of an EU Notified Body. 

The UKCA process is similar in structure to the CE marking process but is assessed against UK regulations rather than MDR. Key differences include:

- Assessment against UK Medical Devices Regulations (not MDR)
- Assessment by a UK Approved Body (not an EU Notified Body)
- UKCA mark on the device (not CE mark, or CE + UKCA)
- Registration with MHRA (not EUDAMED)
- UK Responsible Person required (not EU Authorized Representative) 

### Route 3: Both CE and UKCA

For startups selling in both the EU and the UK, maintaining both marks provides full access to both markets. This means dual conformity assessment — EU Notified Body for CE marking and UK Approved Body for UKCA marking. The documentation may overlap significantly, but the assessments are separate.

## UK-Specific Requirements You Must Meet

Regardless of whether you enter via CE marking or UKCA marking, you must meet certain UK-specific requirements:

### UK Responsible Person

If you are an EU-based manufacturer placing devices on the UK market, you must designate a **UK Responsible Person (UKRP)** — an organization or individual established in the UK who acts on your behalf for regulatory purposes. 

The UKRP role is similar to the EU Authorized Representative role but under UK law. The UKRP:
- Registers the device with MHRA
- Acts as the contact point for MHRA
- Has access to your technical documentation
- Cooperates with MHRA on vigilance and market surveillance matters

### MHRA Device Registration

All medical devices placed on the UK market must be registered with MHRA. This is a separate process from EUDAMED registration in the EU. 

### UK Labeling Requirements

Devices sold in the UK must meet UK-specific labeling requirements, including the manufacturer's or UKRP's UK address. The instructions for use must be in English (which is usually not an issue for products already sold in Ireland or other English-speaking EU markets, but must be verified against UK-specific requirements).

### Vigilance Reporting to MHRA

Adverse incidents with devices on the UK market must be reported to MHRA, not (or in addition to) EU competent authorities. You need a vigilance system that covers UK reporting obligations alongside EU obligations.

## Practical Strategy for EU Startups

### Phase 1: Assess UK Market Priority

Before investing in UK market access, assess whether the UK is a priority market for your startup:

- What is the UK market size for your device?
- Do you have existing UK customers or distribution partners?
- Does your business plan depend on UK revenue in the near term?
- Can you afford the incremental cost of UK-specific regulatory compliance?

For many EU startups, the EU market of 450 million people is the immediate priority, and the UK can wait until the regulatory situation stabilizes.

### Phase 2: Leverage CE Mark Acceptance (If Current)

If CE marking is still accepted in the UK, use it. This is the lowest-cost, fastest route. Appoint a UK Responsible Person, register with MHRA, and start selling.

But do not assume CE mark acceptance is permanent. Plan ahead for the eventual requirement for UKCA marking or UK-specific conformity assessment.

### Phase 3: Prepare for UKCA (When Required)

When UKCA marking becomes mandatory, you will need:
- A UK Approved Body (research and engage early — capacity may be limited)
- Technical documentation adapted to UK regulatory requirements
- UKCA marking on your device and packaging
- Updated labeling with UK-specific information

If your device was CE marked under MDR, much of your technical documentation transfers to the UK assessment — the requirements are similar in substance even if they differ in regulatory reference. The incremental work is primarily the UK Approved Body engagement and UK-specific documentation adaptations.

## UK Approved Body Capacity

One of the biggest challenges for the UKCA marking pathway is UK Approved Body capacity. After Brexit, the UK needed to build its own Approved Body infrastructure from scratch. Progress has been made, but the number of designated UK Approved Bodies remains limited compared to what is needed. 

For startups, this means:
- Plan early — UK Approved Body queue times may be significant
- Research which UK Approved Bodies cover your device type
- Consider whether your EU Notified Body has a UK affiliate or partnership that could streamline the process

## Northern Ireland: The Protocol Complication

Northern Ireland occupies a unique regulatory position due to the Northern Ireland Protocol (now the Windsor Framework). Medical devices placed on the Northern Ireland market must comply with EU MDR and bear the CE mark — Northern Ireland is treated as part of the EU single market for goods. 

Devices can move from Northern Ireland to the rest of the UK (Great Britain), but the rules for doing so have specific requirements. If you sell in Northern Ireland via CE marking, your UK Responsible Person and MHRA registration obligations still apply for the wider UK market.

For most EU startups, this complexity is manageable — if you have CE marking for the EU, you can access Northern Ireland. Accessing Great Britain may require additional steps depending on the current regulatory status.

## The Future Direction

The UK government has signaled its intention to create a modernized medical device regulatory framework. The MHRA published a roadmap for regulatory reform that includes elements drawn from both MDR and the UK's own regulatory approach. 

Key expected developments:
- A new UK-specific regulatory framework (not a direct copy of MDR)
- Software and AI-specific provisions
- Potentially different classification rules
- New post-market surveillance requirements
- Full EUDAMED equivalent for the UK

For EU startups, this means the UK regulatory landscape will continue to evolve. Building flexibility into your UK market access strategy is essential — what applies today may change within a year or two.

Tibor's practical perspective: "The UK market is important but not essential for most EU startups in their first few years. My advice is: get your CE mark first, establish your EU business, and add the UK when the regulatory situation is clearer and your company has the resources to manage a second regulatory jurisdiction. Trying to do both simultaneously as a small startup is a recipe for divided attention and increased cost."

## Cost Considerations

The incremental cost of UK market access for an EU startup:

| Item | Estimated Cost |
|------|---------------|
| UK Responsible Person (annual retainer) | EUR 3,000 - 15,000/year |
| MHRA registration | EUR 1,000 - 5,000 (check current MHRA fees)  |
| UK Approved Body (UKCA, when required) | EUR 15,000 - 80,000 (comparable to EU NB fees for similar class) |
| Labeling adaptations | EUR 2,000 - 10,000 |
| UK-specific documentation | EUR 5,000 - 20,000 |
| **Total (CE route while accepted)** | **EUR 4,000 - 20,000/year** |
| **Total (UKCA route)** | **EUR 25,000 - 130,000 initial + annual** |

These are incremental costs on top of your EU regulatory investment.

## The Bottom Line

Brexit turned one market into two. For EU MedTech startups, the UK remains accessible but requires additional regulatory investment — whether through CE mark recognition (while it lasts) or UKCA marking (when required).

The practical advice: prioritize your EU CE marking, use CE mark acceptance to access the UK market in the short term, and plan strategically for the eventual UKCA requirement based on your UK market importance and resource availability.

The regulatory complexity will stabilize over time. The UK will finalize its framework, the Approved Body infrastructure will mature, and the dual-market path will become routine. Until then, stay informed, stay flexible, and do not let UK regulatory uncertainty distract you from your EU market execution.

---

*This post is part of the [MDR Fundamentals & Regulatory Strategy](https://zechmeister-solutions.com/en/blog/category/mdr-fundamentals) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*